Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Feoifomicose/diagnóstico por imagem , Exophiala , Diabetes Mellitus/tratamento farmacológico , Complicações do Diabetes , Vildagliptina , Metformina , Pacientes Internados , Exame Físico , Doenças Transmissíveis , Microbiologia , Técnicas Microbiológicas , Fungos , MicosesRESUMO
La lobomicosis es una infección cutánea y subcutánea producida por la levadura Lacazzia loboi, que se presenta predominantemente en regiones tropicales, y se caracteriza por la presencia de lesiones nodulares de aspecto queloidiano, de evolución crónica. El diagnóstico se realiza a través del examen directo para hongos o por hallazgos histopatológicos,tinción de PAS y Gomori-Grocott. El hongo no se ha podido cultivar in vitro. El tratamiento para lesiones pequeñas es la escisión quirúrgica o la criocirugía. En lesiones extensas se ha descrito el uso de clofazimina, itraconazol, 5-fluorocitosina, ketoconazol, anfotericina B y sulfonamidas de eliminación lenta. El pronóstico es bueno, con recurrencias tardías. Se reporta el caso de un hombre de 51 años, proveniente de zona rural, quien presentó una lesión típica de esta enfermedad en el dorso de la mano.
Lobomycosis is a skin infection caused by the yeast Lacazzia loboi. It occurs predominantly in tropical regions and is characterized clinically by the presence of nodular lesions similar to keloids, ofchronic evolution. Diagnosis is made through direct examination or histopathological findings, PAS and Grocott -Gomori staining.The fungus has not been cultured in vitro so far. Treatment forsmall lesions is surgical excision or cryosurgery. In extensive lesions the use of clofazimine, itraconazole, 5-fluorocytosine, ketoconazole, amphotericin B and slow-elimination sulfacompounds has been described. The prognosis is good with late recurrences. A case of a 51-year-old from a rural area, who had a typical lesion of this disease on the back of his hand is presented.
Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Ilustração Médica , Micoses/diagnóstico , Micoses/terapia , Relatos de CasosRESUMO
BACKGROUND: Pediculosis capitis is a highly transmissible infestation prevalent worldwide. It is an important public health problem mainly affecting children. The emergence of drug resistance and high rates of treatment failure with several topical agents makes ivermectin, an antiparasitic drug, an attractive therapeutic option for lice control. OBJECTIVE: To evaluate the efficacy and safety of oral ivermectin in the treatment of a pediatric population with pediculosis capitis. METHODS: Children with pediculosis capitis from the ages of 6 to 15 years were recruited from an indigenous community in Mexico, and were treated with a single dose of oral ivermectin at 200 µg/kg. They were treated with a second dose of ivermectin 1 week later if there was evidence of persistent infestation. RESULTS: Forty-four children (mean age, 9.8 years) with active infestation were treated. A single approximately 200-µg/kg dose of ivermectin eradicated adult lice in all children. Forty-one percent (n = 18) required a second dose because of the presence of viable nits. At the third visit, 2 weeks after commencement of treatment there was no evidence of viable nits, and there was complete resolution of excoriations in all children and minimal or no symptoms of pruritus were reported in 93% (n = 41). There were no significant adverse effects due to ivermectin administration. CONCLUSIONS: Ivermectin demonstrates high efficacy and tolerability in the treatment of pediculosis capitis in children. A significant number of children required a second dose to ensure complete eradication.
